The Alfred/Monash Centre For Therapeutics And Clinical Research
Funder
National Health and Medical Research Council
Funding Amount
$2,000,000.00
Summary
The Centre will provide a national resource for the evaluation of new and existing drugs. It will focus particularly on investigator-initiated research that is not well served by present funding arrangements. With the cost of pharmaceuticals rising at an annual rate of 15-20 percent there is a clear need for independently developed, comparative information on both new and existing agents. It will also address the virtual absence in Australia of a major academic research focus on drug safety and ....The Centre will provide a national resource for the evaluation of new and existing drugs. It will focus particularly on investigator-initiated research that is not well served by present funding arrangements. With the cost of pharmaceuticals rising at an annual rate of 15-20 percent there is a clear need for independently developed, comparative information on both new and existing agents. It will also address the virtual absence in Australia of a major academic research focus on drug safety and pharmacoeconomics.Read moreRead less
Mortality Among Injecting Drugs Users - A Follow-up Study Of Injecting Drug User Cohorts.
Funder
National Health and Medical Research Council
Funding Amount
$47,500.00
Summary
This study will follow-up injecting drug users that participated in research in the 1990s and 2000s to examine mortality rates in these groups over time. Identifying information from these studies will be cross-referenced with National Death Index data to determine participants that died and the dates of their death. This study will be the first in Australia to determine mortality rates over time in a defined cohort of injecting drug users outside drug treatment settings. Studying a defined grou ....This study will follow-up injecting drug users that participated in research in the 1990s and 2000s to examine mortality rates in these groups over time. Identifying information from these studies will be cross-referenced with National Death Index data to determine participants that died and the dates of their death. This study will be the first in Australia to determine mortality rates over time in a defined cohort of injecting drug users outside drug treatment settings. Studying a defined group overcomes some of the problems associated with mortality rate estimates based simply on the number of injecting drug-related deaths. Although the number of deaths can be found, the number of people at risk of injecting drug-related death is unclear because of the hidden nature of drug use and the dynamic characteristics of drug use and drug markets. The examination of mortality trends among injecting drug users over time can provide insights regarding changes in drug use patterns and markets. For example, this study will examine changes in injecting drug use mortality across periods of high heroin availability in the late '90s and periods of interrupted heroin supply - the heroin 'drought' - from 2000 onwards. In addition, factors related to injecting drug-related mortality can be explored by comparing the characteristics of injecting drug users that died and those that survived, such as drug use and drug treatment histories, co-morbidities such as mental illness and socio-demographic backgrounds. This information can inform overdose prevention and harm reduction strategies by identifying individuals most at risk of injecting drug-related mortality. This study will also draw attention to the significant public health burden of injecting drug use. In addition, by comparing the results from this study with other similar studies from overseas, we can more reliably compare mortality among groups of Australian injecting drug users with their peers in other countries.Read moreRead less
Improving The Health Of People With Problematic Drug Use: Hepatitis C And Drug Dependence
Funder
National Health and Medical Research Council
Funding Amount
$9,060,140.00
Summary
Problematic drug use is the major risk factor to health among Australians aged 15-49 years. The dual harms of drug dependence and hepatitis C virus (HCV) faced by people who use drugs compel improved drug dependence management and HCV prevention and treatment. This Program Grant will improve the lives of people with problematic drug use by investigating health impacts of drug use and evaluating new strategies for managing drug dependence and eliminating HCV among people who use drugs.
Population-level Vaccine Safety Monitoring: Risk Assessment And Policy Implications
Funder
National Health and Medical Research Council
Funding Amount
$85,649.00
Summary
Vaccines prevent millions of deaths worldwide but events can occur after vaccination which may or may not be related to the vaccine. It is vital to ensure vaccines are safe and that both the public and medical providers remain confident in vaccination programs. The PhD thesis will look at the various methods for monitoring vaccine safety in Australia, and compare the usefulness of each system. This will provide information for policy makers on the safety of vaccines in Australia.
Toward A Comprehensive Picture Of The Epidemiology Of Alcohol And Illicit Drug Use Disorders: Novel Analyses Of The World Health Organization's World Mental Health Surveys
Funder
National Health and Medical Research Council
Funding Amount
$734,155.00
Summary
Alcohol and illicit drug use are among the biggest risk factors for disease burden, but there is much that is not known about the natural history of substance use. This study involves analysis of data from the WHO World Mental Health Survey (WMHS) initiative, which contains data on >160,000 participants from more than 31 countries. This study will examine the patterns and predictors of substance use problems, using novel statistical techniques predict who is at greatest risk.
Molecular Epidemiology Of Mycobacterium Tuberculosis Infection In The Northern Territory, Australia
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
The Northern Territory (NT) of Australia has the highest jurisdiction-specific rates of tuberculosis (TB) in Australia, and TB is a disease that disproportionately affects Indigenous people. The factors that contribute to the spread of TB in the NT are incompletely understood. We plan to use technology known as “whole genome sequencing” of bacterial DNA to better the understanding of the spread of TB in the NT. This will help guide TB control policies.
Quantifying And Reducing The Burden Of New And Emerging Psychoactive Substances In Australia
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
The public health threat posed by emerging drugs of concern (e.g., new psychoactive substances (NPS) and crystalline methamphetamine) requires timely and effective public health interventions. This research program will strengthen estimates of the global NPS health burden, enhance the surveillance of unwitting drug consumption, and develop and evaluate novel harm reduction responses. Findings will inform policy and health service delivery, both globally and within Australia.